Novartis is to acquire a group of assets directed against inflammatory diseases following the acquisition of IFM Due Inc, a Boston, US-based biotech incubator. The deal is valued at up to $835 million. IFM Due is a subsidiary of IFM Therapeutics Inc, a company that was set up by scientists and venture capitalists in 2015 to discover and develop small molecules modulating targets in the innate immune system, the body’s first line of defence against pathogens.
